Cannabis Pharma Market to Hit $111 Billion by 2032: Industry Report

An Industry on the Verge of Explosive Growth

A new research report has put a staggering number on the future of cannabis pharmaceuticals: $111.1 billion by 2032. That figure represents growth from just $4.7 billion in 2025, implying a compound annual growth rate of 57.1 percent over a seven-year period. Even accounting for the optimistic projections that market research firms sometimes produce, the trajectory is striking and reflects a convergence of regulatory shifts, scientific breakthroughs, and changing public attitudes that are fundamentally reshaping the cannabis industry.

The report, published by Global Industry Analysts, highlights key players including AbbVie, Aurora Cannabis, Bausch Health, and Canopy Growth as companies positioned to benefit from this expansion. But the story is bigger than any single company. It is about an entire sector transitioning from the fringes of the pharmaceutical world into what could become one of its most dynamic segments.

What Is Driving This Growth

Several factors are converging to create conditions for unprecedented expansion in cannabis pharmaceuticals.

The most significant catalyst is the federal rescheduling of certain marijuana products to Schedule III, finalized by the Department of Justice on April 23, 2026. This single regulatory change has massive implications for the pharmaceutical side of the cannabis industry. Schedule III classification allows cannabis companies to deduct ordinary business expenses like rent, payroll, and marketing — a tax benefit that has been denied to cannabis businesses operating under the punitive Section 280E of the tax code. For pharmaceutical companies specifically, Schedule III opens more accessible pathways for FDA-approved drug development.

The broader cannabis-infused products market is also expanding rapidly, growing from $33.62 billion in 2025 to a projected $41.44 billion in 2026, representing a 23.2 percent year-over-year increase. This growth in consumer products creates a foundation of market demand and consumer acceptance that pharmaceutical companies can build upon.

Scientific research is accelerating in parallel. Over 100 notable cannabis studies have been published in 2026 alone, covering applications from cancer treatment to chronic pain to sleep disorders. Each positive finding adds to the body of evidence that supports FDA approval processes for cannabis-based pharmaceuticals.

The Rescheduling Effect

The move to Schedule III cannot be overstated in its importance to the cannabis pharmaceutical sector. Under Schedule I, cannabis was classified alongside heroin and LSD, with the federal government's official position being that it had no accepted medical use. This classification created enormous obstacles for pharmaceutical companies attempting to develop cannabis-based medications.

With Schedule III status, the regulatory pathway looks dramatically different. Companies can now conduct research with fewer bureaucratic hurdles, apply for FDA approval through established pharmaceutical channels, and access the kind of institutional funding and partnerships that were previously off-limits.

The upcoming DEA hearing on June 29, which will consider whether to reschedule all marijuana — including recreational products — from Schedule I to Schedule III, could further accelerate this transformation. If broader rescheduling occurs, it would create an even larger addressable market for pharmaceutical companies developing cannabis-based treatments.

Company Earnings Tell the Story

Recent corporate earnings reports provide tangible evidence that the cannabis pharmaceutical sector is already gaining momentum. Cronos Group reported first-quarter 2026 net revenue of $45.2 million, representing a 40 percent increase year over year. Even more notably, the company posted net income of $15.7 million, demonstrating that profitability in the cannabis pharmaceutical space is not just a future aspiration but a present reality for well-positioned operators.

These numbers are particularly significant in the context of an industry that has been characterized by cash burn and operating losses for much of its existence. The shift toward profitability suggests that the cannabis pharmaceutical sector is maturing beyond its startup phase and beginning to operate on the financial fundamentals that attract serious institutional investment.

Therapeutic Areas Driving Demand

The pharmaceutical applications of cannabis extend across a wide range of therapeutic areas, each representing a significant market opportunity.

Pain management remains the largest single application, with cannabinoid-based treatments competing against opioids and other analgesics in a market that is actively seeking safer alternatives. The ongoing opioid crisis has created both public demand and regulatory willingness to explore cannabis-based pain treatments as part of harm reduction strategies.

Neurological conditions represent another major growth area. Epidiolex, the first FDA-approved cannabis-derived medication, treats rare forms of epilepsy and has demonstrated the viability of the regulatory pathway for cannabis pharmaceuticals. Research into cannabis applications for conditions like multiple sclerosis, Parkinson's disease, and PTSD continues to expand the potential therapeutic portfolio.

Oncology is emerging as a particularly promising frontier. Recent research showing that THC and CBD can enhance the effectiveness of certain chemotherapy drugs has generated significant interest from pharmaceutical companies and oncologists. If these findings are confirmed in larger clinical trials, they could open a massive new market for cannabis-based adjunct cancer therapies.

Mental health applications, including treatments for anxiety, insomnia, and depression, round out the major therapeutic categories. A 2026 clinical trial finding that a cannabis-based formula performed comparably to lorazepam for chronic insomnia suggests that cannabis pharmaceuticals could eventually compete in the lucrative sleep and anxiety medication markets.

Challenges and Risks

Despite the optimistic projections, significant challenges remain. The regulatory landscape continues to evolve unpredictably. While Schedule III classification is a major step forward, full federal legalization remains uncertain, and the patchwork of state regulations creates complexity for companies operating across multiple jurisdictions.

Clinical trial requirements for FDA approval remain rigorous and expensive. Cannabis's complex pharmacology — with over 100 cannabinoids and hundreds of terpenes interacting in ways that are not yet fully understood — makes standardization and dosing precision particularly challenging for pharmaceutical development.

Market competition is also intensifying. As the sector becomes more attractive, established pharmaceutical companies with deeper pockets and more regulatory experience may increasingly compete with cannabis-native companies, potentially squeezing margins and market share for smaller operators.

Intellectual property challenges are another concern. The natural origin of cannabis compounds makes patent protection more difficult than for synthetic molecules, which could limit the ability of companies to capture monopoly pricing that typically drives pharmaceutical profitability.

What This Means for the Industry

The $111 billion projection is not just a number. It represents a fundamental reordering of how the world thinks about cannabis — from a controlled substance to a pharmaceutical ingredient with therapeutic applications spanning dozens of conditions and affecting millions of patients.

For investors, the numbers suggest that the cannabis pharmaceutical sector may be entering its most significant growth phase. For patients, it means more treatment options backed by rigorous clinical evidence. For regulators, it underscores the importance of developing frameworks that facilitate innovation while maintaining safety standards.

The next several years will determine whether this projection materializes or proves overly optimistic. But the underlying trend — cannabis moving from counterculture to mainstream pharmaceutical ingredient — appears irreversible. The companies, researchers, and regulators who position themselves effectively now will be the ones shaping the industry when that $111 billion future arrives.

Looking for a licensed shop near you? Browse Budpedia's directory of verified cannabis dispensaries to find a dispensary in your area.